AI-Designed TB treatment aims for 99.5% cure rate
NCT ID NCT07467252
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial tests whether an AI-optimized combination of pyrazinamide and hydroxychloroquine works better than the standard four-drug RIPE regimen for newly diagnosed drug-sensitive pulmonary tuberculosis. Two hundred adults will receive either the new AI-personalized treatment or standard care for 6 months, with follow-up for another 6 months. The study aims to see if the new combo clears the bacteria faster and causes fewer liver side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pyrazinamide and hydroxychloroquine
What this could lead to
If successful, this could lead to a more effective and safer treatment for tuberculosis, potentially curing more patients with fewer side effects.
What could go wrong
This is a Phase II trial with only 200 participants, so results may not apply to everyone. The AI-optimized dosing is new and unproven in humans, and hydroxychloroquine has known risks like heart rhythm problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Riyadh First Health Cluster, Ministry of Health
Riyadh, Riyadh Region, 11176, Saudi Arabia
Contact Phone: •••-•••-•••• Email: •••••@•••••